[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335553-105":59,"doc-detail-335553-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-profiling-and-expanded-use-of-targeted-anticancer-drugs-in-solid-cancers-with-exhausted-evidence-based-treatment-options-precode-study-protocol-of-a-prospective-non-randomized-cohort-study","Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE) - study protocol of a prospective, non-randomized, cohort study","","Genomic profiling for advanced solid cancer patients without further evidence-based standard treatment options is evaluated as a novel way to identify experimental therapies based on specific genomic alterations. Given the expected short survival of these patients, rapid assessment of druggable targets is essential to reduce deterioration risk during analysis. This prospective primary study measures genomic profiling turnaround time and related clinical procedures, while secondary aims assess match frequency to treatment offers and clinical outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-profiling-and-expanded-use-of-targeted-anticancer-drugs-in-solid-cancers-with-exhausted-evidence-based-treatment-options-precode-study-protocol-of-a-prospective-non-randomized-cohort-study/335553/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-profiling-and-expanded-use-of-targeted-anticancer-drugs-in-solid-cancers-with-exhausted-evidence-based-treatment-options-precode-study-protocol-of-a-prospective-non-randomized-cohort-study/335553.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary objective of the PRECODE study?","Question",{"text":112,"@type":113},"To evaluate turnaround time for genomic profiling and the clinical investigational procedures.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is genomic profiling performed in the study?",{"text":117,"@type":113},"A core needle biopsy is analyzed by next generation sequencing using a pan-cancer comprehensive panel.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main eligibility criteria for participants?",{"text":121,"@type":113},"Age ≥ 18 years, written informed consent, advanced solid tumors with exhausted treatment options, ECOG 0–2, adequate organ function, and life expectancy of at least 3 months.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335553,1790445869,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Hansen et al. BMC Medical Genomics (2024) 17:274  \n[https://doi.org/10.1186/s12920-024-02033-z](https://doi.org/10.1186/s12920-024-02033-z)  \nBMC Medical Genomics  \n STUDY PROTOCOL Open Access  \nGenomic profiling and expanded  \nuse of targeted anticancer drugs in solid  \ncancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study  \nKarin Holmskov Hansen1*, Maria Bibi Lyng2, Annette Raskov Kodahl1,3, Jon Thor Asmussen4, Arman Arshad5, Henrik Petersen6, Lotte Krogh7, Sidse Ehmsen 1,3, Thomas Kielsgaard Kristensen2,8 and Henrik J. Ditzel 1,3  \nAbstract  \nBackground Genomic profiling of advanced solid cancer in patients with no further evidence based standard treatment options is a novel approach to identify potential experimental treatment options based on specific genomic alterations. Due to the expected short survival of these patients timely assessment of potential druggable targets is critical to minimize the risk of deterioration during the analysis.  \nThe primary objective of this prospective study is to evaluate the turnaround time for genomic profiling and the clinical investigational procedures. The secondary objectives are to investigate how often genomic alterations in tumor tissue gives rise to a matched treatment offer and evaluate the clinical outcome.  \nMethods The PRECODE study is a prospective, non-randomized, single-center cohort study conducted at Departments of Oncology and Pathology, Odense University Hospital, Denmark. Enrollment between March  \n1, 2019 and December 31, 2024. Eligibility criteria are age ≥ 18 years, written informed consent, advanced solid tumors, exhausted treatment options, ECOG performance status 0–2, adequate organ function and life expectancy ≥ 3 months. A core needle biopsy is analyzed by next generation sequencing using a pan-cancer comprehensive panel. Results are discussed weekly at institutional/local and national multidisciplinary tumor boards.  \nDiscussion Strategies and methods for genomic profiling of advanced solid cancers differ. Rapid analysis and interpretation of sequencing data are key to avoiding delays in initiation potential experimental treatments, as these latestage patients may quickly deteriorate.  \nAlthough a highly optimized setup with fast-track clinical evaluation and genomic profiling has been established a subset will not be offered a targeted treatment due to deterioration. Local and national multidisciplinary teams have been established to optimize individualized treatment decisions. After genomic profiling a subset of patients will take part in clinical trials, which will constrain the reporting of overall survival or progression free survival.  \n*Correspondence:  \nKarin Holmskov Hansen  \n[holmskov-hansen@hotmail.com](holmskov-hansen@hotmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-n","cbCaidgp2hrdkFGW","https://ap.wps.com/l/cbCaidgp2hrdkFGW","pdf",1741487,"English","# Background\n## Study objectives\n# Methods\n## Eligibility and enrollment\n## Genomic testing and review process\n# Discussion\n## Rationale and operational considerations\n## Clinical trial reporting constraints","[{\"question\":\"What is the primary objective of the PRECODE study?\",\"answer\":\"To evaluate turnaround time for genomic profiling and the clinical investigational procedures.\"},{\"question\":\"How is genomic profiling performed in the study?\",\"answer\":\"A core needle biopsy is analyzed by next generation sequencing using a pan-cancer comprehensive panel.\"},{\"question\":\"What are the main eligibility criteria for participants?\",\"answer\":\"Age ≥ 18 years, written informed consent, advanced solid tumors with exhausted treatment options, ECOG 0–2, adequate organ function, and life expectancy of at least 3 months.\"}]","Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE) - study protocol of a prospective, non-randomized, cohort study | PDF",1790011419,23]